Why Tractor Supply Company Shares Are Falling After Q1 Earnings
Tractor Supply Company shares decline despite beating Q1 earnings expectations, as slowing comparable store sales growth and cautious FY24 outlook weigh on investor sentiment.
Why Is Equipment Giant Caterpillar Stock Plunging Today?
Caterpillar reported Q1 fiscal 2024 revenue of $15.8B, down 0.4% YoY and missing consensus. Adjusted earnings of $5.60 per share beat consensus. Sales dropped due to reduced equipment sales and adverse currency impacts.
Intel Spinoff Mobileye Revenue Falls Amid Supply Chain Reset, CEO Optimistic About Recovery
Mobileye reported Q1 2024 revenue of $239M, beating consensus of $231.56M. Adjusted EPS missed consensus at $(0.07). FY24 outlook reiterated, stock down 31%
Drugmaker Sanofi’s Strong Dupixent And Beyfortus Vaccine Sales Propel Q1 Earnings
Sanofi reports Q1 operating income at 2.8 billion euros, down 14.7%. Beat consensus EPS at $0.97. Sales reach $11.36 billion, led by Dupixent's 24.9% surge. Vaccine sales up 5.6%. Expecting Dupixent to hit €13 billion in 2024 sales. Blockbuster ambitions for Beyfortus.
What’s Going On With Harley-Davidson Shares After Q1 Results?
Harley-Davidson shares dip despite beating Q1 earnings and revenue estimates, citing planned motorcycle shipment decrease.
Why Beverage Company Keurig Dr Pepper’s Shares Are Surging Today
Keurig Dr Pepper impresses investors with a 3.5% year-on-year sales surge to $3.47 billion in Q1 FY24, outperforming analyst predictions. Notably, U.S. Refreshment Beverages lead the growth trajectory with a 4.3% rise to $2.1 billion.
Brunswick Falls Over 2% After Q1 Earnings – Here’s Why
Brunswick Corporation's shares decline over 2% premarket as Q1 earnings show sales dip and adjusted operating margin contraction.
Why Is American Airlines Stock Seeking Blue Skies Today?
American Airlines reported Q1 financial results with a midpoint above estimates. Revenue increased but adjusted EPS missed consensus. Company reduced debt and expects 2024 adjusted EPS of $1.15-$1.45 and reiterated FY24 outlook of $2.25-$3.25.
AstraZeneca Posts Bumper Earnings On Strong Sales From Cancer Drugs, Sticks To Annual Guidance
AstraZeneca reports Q1 sales of $12.68 billion, up 17% Y/Y. Despite missing adjusted EPADS, oncology sees a 26% surge, driven by Tagrisso and Imfinzi. Cardiovascular sales up 20%. R&D up 18%. Fiscal 2024 outlook: low double-digit revenue and EPS growth.
Not All Chipmakers Are Doing Great; STMicroelectronics Lowers Annual Outlook After Q1 Performance
STM reported 18.4% revenue decline in Q1 2024, missed consensus estimates. Margins decreased and outlook for Q2 and 2024 is lower than expected.